Committed memory effector type 2 cytotoxic T (Tc2) cells are ineffective in protective anti-tumor immunity

Immunology Letters

Volumn 95, Issue 1, 2004, Pages 77-84

  Do, Jeong Su ^a   Choi, Youn Hwa ^a   Shin, Sung Hye ^b   Yi, Ho Keun ^c   Hwang, Pyung Han ^c   Nam, Sang Yun ^a  

^a Jeonju University   (South Korea)

^b Presbyterian Medical Center   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

Author keywords

Anti tumor activity; CD8; Memory cells; T cells; Tc1 Tc2 cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL POLARITY; CELL STIMULATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; INTERFERON PRODUCTION; LYMPHOCYTE DIFFERENTIATION; MALE; MEMORY CELL; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; TH2 CELL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 4344672937     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2004.06.006     Document Type: Article

References (45)

1. R.J. Barth Jr., J.J. Mule, P.J. Spiess, and S.A. Rosenberg Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes J. Exp. Med. 173 1991 580 647
2. S.A. Rosenberg, P. Spiess, and R. Lafreniere A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 1986 1318 1321
3. D.H. Lynch, and R.E. Miller Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo J. Exp. Med. 179 1994 31 42
4. I.M. Svane, M. Boesen, and A.M. Engel The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors - lessons from normal and immunodeficient mice Med. Oncol. 16 1999 223 238
5. J.I. Mayordomo, T. Zorina, W.J. Storkus, L. Zitvogel, C. Celluzzi, L.D. Falo, C.J. Melief, S.T. Ildstad, W.M. Kast, and A.B. Deleo Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat. Med. 1 1995 1297 1302
6. P. Paglia, C. Chiodoni, M. Rodolfo, and M.P. Colombo Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo J. Exp. Med. 183 1996 317 322
7. A. Porgador, D. Snyder, and E. Gilboa Induction of antitumor immunity using bone marrow-generated dendritic cells J. Immunol. 156 1996 2918 2926
8. T.R. Mosmann, and R.L. Coffman TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties Annu. Rev. Immunol. 7 1989 145 173
9. M. Croft, L. Carter, S.L. Swain, and R.W. Dutton Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles J. Exp. Med. 180 1994 1715 1728
10. S. Sad, R. Marcotte, and T.R. Mosmann Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines Immunity 2 1995 271 279
11. C. Vizler, N. Bercovici, A. Heurtier, N. Pardigon, K. Goude, K. Bailly, C. Combadiere, and R.S. Liblau Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts J. Immunol. 165 2000 6314 6321
12. D.H. Fowler, J. Breglio, G. Nagel, M.A. Eckhaus, and R.E. Gress Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease J. Immunol. 157 1996 4811 4821
13. P.D. Greenberg Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells Adv. Immunol. 49 1991 281 355
14. U. Ucer, H. Bartsch, P. Scheurich, and K. Pfizenmaier Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression Int. J. Cancer. 36 1985 103 108
15. A. Aruga, E. Aruga, K. Tanigawa, D.K. Bishop, V.K. Sondak, and A.E. Chang Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role J. Immunol. 159 1997 664 673
16. W.S. Hong, J.R. Jett, Y. Sasaki, H. Takahashi, H. Nakano, K. Nakagawa, A. Hoshi, and N. Saijo Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines Jpn. J. Clin. Oncol. 17 1987 49 55
17. P. Mongini, S. Seremetis, C. Blessinger, S. Rudich, R. Winchester, and M. Brunda Diversity in inhibitory effects of IFN-gamma and IFN-alpha A on the induced DNA synthesis of a hairy cell leukemia B lymphocyte clone reflects the nature of the activating ligand Blood 72 1988 1553 1559
18. M.J. Brunda, L. Luistro, J.A. Hendrzak, M. Fountoulakis, G. Garotta, and M.K. Gately Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12 J. Immunother. Emphasis Tumor Immunol. 17 1995 71 77
19. S. Sad, D. Kagi, and T.R. Mosmann Perforin and Fas killing by CD8+ T cells limits their cytokine synthesis and proliferation J. Exp. Med. 184 1996 1543 1547
20. L.L. Carter, and R.W. Dutton Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations J. Immunol. 155 1995 1028 1031
21. M.J. Dobrzanski, J.B. Reome, and R.W. Dutton Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases J. Immunol. 162 1999 6671 6680
22. M.J. Dobrzanski, J.B. Reome, and R.W. Dutton Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection J. Immunol. 167 2001 424 434
23. B.K. Helmich, and R.W. Dutton The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors J. Immunol. 166 2001 6500 6508
24. R.A. Kemp, and F. Ronchese Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity J. Immunol. 167 2001 6497 6502
25. D.C. Cronin 2nd, R. Stack, and F.W. Fitch IL-4-producing CD8+ T cell clones can provide B cell help J. Immunol. 154 1995 3118 3127
26. F. Erard, M.T. Wild, J.A. Garcia-Sanz, and G. Le Gros Switch of CD8 T cells to noncytolytic CD8-CD4- cells that make TH2 cytokines and help B cells Science 260 1993 1802 1805
27. S. Sad, and T.R. Mosmann Interleukin (IL) 4 in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines J. Exp. Med. 182 1995 1505 1515
28. J.H. Park, S.H. Chang, K.M. Lee, and H.K. Lee Murine Sarcoma Cells Transfected with Interleukin 12 are Rejected in vivo Inducing Protective and Curative Immune Responses against the parental cells Mol. Cell. 5 1995 595 601
29. A. Cerwenka, L.L. Carter, J.B. Reome, S.L. Swain, and R.W. Dutton In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines J. Immunol. 161 1998 97 105
30. Y. Kawakami, S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes J. Exp. Med. 180 1994 347 352
31. B. Fisk, T.L. Blevins, J.T. Wharton, and C.G. Ioannides Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J. Exp. Med. 181 1995 2109 2117
32. K. Devaraj, M.L. Gillison, and T.C. Wu Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma Crit. Rev. Oral Biol. Med. 14 2003 345 362
33. W. Osen, T. Peiler, P. Ohlschlager, S. Caldeira, S. Faath, N. Michel, M. Muller, M. Tommasino, I. Jochmus, and L. Gissmann A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity Vaccine 19 2001 4276 4286
34. L.C. Peters, J.S. Brandhorst, and M.G. Hanna Jr. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors Cancer Res. 39 1979 1353 1360
35. H.C. Hoover Jr., J.S. Brandhorst, L.C. Peters, M.G. Surdyke, Y. Takeshita, J. Madariaga, L.R. Muenz, and M.G. Hanna Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial J. Clin. Oncol. 11 1993 390 399
36. E. Gilboa, H.K. Lyerly, J. Vieweg, and S. Saito Immunotherapy of cancer using cytokine gene-modified tumor vaccines Semin. Cancer Biol. 5 1994 409 417
37. J.R. Yannelli, C. Hyatt, S. Johnson, P. Hwu, and S.A. Rosenberg Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2) J. Immunol. Methods 161 1993 77 90
38. X. Zhang, T. Brunner, L. Carter, R.W. Dutton, P. Rogers, L. Bradley, T. Sato, J.C. Reed, D. Green, and S.L. Swain Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis J. Exp. Med. 185 1997 1837 1849
39. M. Vukmanovic-Stejic, B. Vyas, P. Gorak-Stolinska, A. Noble, and D.M. Kemeny Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes Blood 95 2000 231 240
40. P. Gorak-Stolinska, J.P. Truman, D.M. Kemeny, and A. Noble Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha J. Leukoc. Biol 70 2001 756 766
41. R.I. Tepper, P.K. Pattengale, and P. Leder Murine interleukin-4 displays potent anti-tumor activity in vivo Cell 57 1989 503 512
42. T. Nishimura, M. Nakui, M. Sato, K. Iwakabe, H. Kitamura, M. Sekimoto, A. Ohta, T. Koda, and S. Nishimura The critical role of Th1-dominant immunity in tumor immunology Cancer Chemother Pharmacol. 46 Suppl. 2000 S52 S61
43. G. Trinchieri Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes Blood 84 1994 4008 4027
44. T. Nishimura, K. Watanabe, U. Lee, T. Yahata, K. Ando, M. Kimura, Y. Hiroyama, M. Kobayashi, S.H. Herrmann, and S. Habu Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor Immunol. Lett. 48 1995 149 152
45. G. Gri, C. Chiodoni, E. Gallo, A. Stoppacciaro, F.Y. Liew, and M.P. Colombo Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15 Cancer Res. 62 2002 4390 4397